Company news

Radiopharm Theranostics Limited news in 2026

Radiopharm Theranostics Limited's news releases, calls and decks from 2026, newest first.

View company

RAD Alignment with US FDA for Development of RAD101

November 3, 2026

RAD Alignment with US FDA for Development of RAD101

November 3, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 30, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 30, 2026

Notice of Annual General Meeting/Proxy Form

October 26, 2026

Radiopharm receives $8M advance on FY26 R&D tax incentive

October 26, 2026

Notification regarding unquoted securities - RAD

October 20, 2026

Change of Director's Interest Notices x 4

October 20, 2026

Notification of cessation of securities - RAD

October 20, 2026

Non-Compliance with Listing Rule 10.11

October 11, 2026

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

October 5, 2026

RAD Completes Meeting with US FDA for Development of RAD101

October 4, 2026

Notification of cessation of securities - RAD

October 1, 2026

Change of Director's Interest Notice (RC)

October 1, 2026

Appendix 4G and Corporate Governance Statement

September 30, 2026

Annual Report and Form 20-F

September 30, 2026

Change of Director's Interest Notices x 4

September 22, 2026

Notification regarding unquoted securities - RAD

September 16, 2026

RADOC New Class Options Range of Units and Top 20 Holders

September 16, 2026

Application for quotation of securities - RAD

September 16, 2026

Application for quotation of securities - RAD

September 16, 2026

Share purchase plan completed

September 16, 2026

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

September 14, 2026

RAD oral presentation at SNO26 on RAD101 Phase IIb data

September 13, 2026

Results of Meeting

September 10, 2026

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

September 9, 2026

RAD Announces Positive Data from RAD301 P1 Imaging Trial

September 8, 2026

Appendix 4E and Preliminary Final Report

August 28, 2026

Change of Director's Interest Notices x 4

August 27, 2026

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

August 26, 2026

RAD Doses First Patient in Second Cohort of BetaBart (RV-01)

August 25, 2026

Ceasing to be a substantial holder

August 24, 2026

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

August 20, 2026

RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial

August 19, 2026

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

August 17, 2026

Change in substantial holding

August 17, 2026

RAD to meet with US FDA to align on RAD 101 Phase 3 Trial

August 16, 2026

Notice of Extraordinary General Meeting and Proxy Form

August 12, 2026

Share Purchase Plan - Now Open

August 6, 2026

Update - Proposed issue of securities - RAD

August 4, 2026

Application for quotation of securities - RAD

August 2, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 30, 2026

Change in substantial holding

July 30, 2026

Target market determination (TMD)

July 30, 2026

Prospectus

July 30, 2026

Notice Under Section 708A

July 28, 2026

Application for quotation of securities - RAD

July 27, 2026

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up to Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

July 27, 2026

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

July 24, 2026

RAD completes A$12.5 M placement and launches A$6 M SPP

July 24, 2026

Older news releases →

Decks in 2026